title: MRSA prevention strategies and current guidelines.
abstract: We review prevention strategies to minimise the risk of MRSA soft tissue and bone infections, which can be devastating for the patient and costly for the healthcare provider. Department of Health (England) policy is that screening for emergency admissions will be mandatory from 2011, in addition to existent elective admission screening. Rapid screening technology has not been shown to be cost-effective, meaning that there will be a lag time between admission and the patient's MRSA status being known. Thus, standard infection control policies regarding isolation of high-risk patients will remain, with a continuing focus on MRSA decolonisation, aimed at minimising the risks of auto-infection and transmission to other patients. Antimicrobial prescribing policies should be designed to take into account the local burden of resistant organisms, but also minimise unnecessary antibiotic use. There is an increasing realisation that reducing the use of fluoroquinolones and third-generation cephalosporins (which have been associated with increased carriage of MRSA) in patient populations where MRSA is prevalent can be a useful control measure. Prevention of orthopaedic infections clearly involves general operating theatre protocols, such as suitable antiseptic skin preparation, and additional measures including the use of laminar airflow. Antibiotic prophylaxis is adjusted in patients known to have MRSA to include a glycopeptide, and local guidelines may adopt such regimens for all patients due to the burden of MRSA in the local patient population. A future development that may have an effect on practice is the development of a Staphylococcus aureus vaccine, which has been shown to be cost-effective in a computer-modelled evaluation.
authors.affiliation: Department of Medical Microbiology, Leeds Teaching Hospitals & University of Leeds, UK.
authors.forename: F M
authors.initials: FM
authors.lastname: Byrne
authors.forename: M H
authors.initials: MH
authors.lastname: Wilcox
mesh_terms: D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002353:Carrier State / Q000175:diagnosis*; D004739:England; D017408:Guidelines as Topic; D006801:Humans; D017053:Infection Control / Q000191:economics* / Q000379:methods*; D008403:Mass Screening / Q000191:economics; D055624:Methicillin-Resistant Staphylococcus aureus; D010356:Patient Isolation / Q000191:economics; D012307:Risk Factors; D013203:Staphylococcal Infections / Q000517:prevention & control*
chemical_list: D000900:Anti-Bacterial Agents